Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.55 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.52 |
| ▸ | CASP2 | P42575 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | MDH1 | P40925 | 1/20 | 0.47 |
| ▸ | MDH2 | P40926 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417133 | 0.93 | MEN1 (0.62) | MEN1KMT2ARAB9AL3MBTL1LMNA | |
| SCHEMBL11706453 | 0.92 | MEN1 (0.60) | MEN1KMT2ARAB9AL3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL11702177 | 0.92 | MEN1 (0.63) | MEN1KMT2ARAB9AL3MBTL1LMNA | |
| SCHEMBL11702997 | 0.90 | MEN1 (0.59) | MEN1KMT2ARAB9AL3MBTL1LMNA | |
| SCHEMBL421046 | 0.85 | MEN1 (0.76) | MEN1KMT2ARAB9AL3MBTL1LMNA | |
| SCHEMBL1083023 | 0.85 | MEN1 (0.76) | MEN1KMT2ARAB9AL3MBTL1LMNA | |
| SCHEMBL11702166 | 0.84 | MEN1 (0.62) | MEN1KMT2ARAB9AL3MBTL1LMNA | |
| SCHEMBL11701921 | 0.84 | MEN1 (0.74) | MEN1KMT2ARAB9AL3MBTL1LMNA | |
| SCHEMBL11704564 | 0.80 | MEN1 (0.68) | MEN1KMT2ARAB9AL3MBTL1LMNA | |
| SCHEMBL11704369 | 0.79 | MEN1 (0.66) | MEN1KMT2ARAB9AL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| US-20200031764-A1 | NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2020-01-30 | — | — | US | disclosed |
| WO-2018164549-A1 | NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | 동국대학교 산학협력단 | 2018-09-13 | — | — | WO | disclosed |
| US-9789114-B2 | Compounds as HIF-1α inhibitors and manufacturing process thereof | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-10-17 | — | — | US | disclosed |
| US-20160193215-A1 | NOVEL COMPOUNDS AS HIF-1 ALPHA INHIBITORS AND MANUFACTURING PROCESS THEREOF | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-07-07 | — | — | US | disclosed |
| US-9315507-B2 | Compounds as HIF-1alphainhibitors and manufacturing process thereof | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-04-19 | — | — | US | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140228357-A1 | NOVEL COMPOUNDS AS HIF-1ALPHAINHIBITORS AND MANUFACTURING PROCESS THEREOF | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2014-08-14 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031764-A1 | NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | MDH2, MDH1, ALDH5A1 | MEN1 1274/4885KMT2A 1497/4885RAB9A 2374/4885 |
| US-20160193215-A1 | NOVEL COMPOUNDS AS HIF-1 ALPHA INHIBITORS AND MANUFACTURING PROCESS THEREOF | HIF1AN, HIF1A, VEGFA | MEN1 3424/4885KMT2A 1584/4885RAB9A 1498/4885 |
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | MDH2, MDH1, ME2 | MEN1 1609/4885KMT2A 658/4885RAB9A 2748/4885 |
| US-20140228357-A1 | NOVEL COMPOUNDS AS HIF-1ALPHAINHIBITORS AND MANUFACTURING PROCESS THEREOF | HIF1AN, HIF1A, VEGFA | MEN1 3180/4885KMT2A 1710/4885RAB9A 1362/4885 |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | MEN1 844/4885KMT2A 4433/4885RAB9A 2650/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | MEN1 844/4885KMT2A 4433/4885RAB9A 2650/4885 |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | HIF1AN, HIF1A, VHL | MEN1 3620/4885KMT2A 1390/4885RAB9A 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.